---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-23-000297"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2023-03-03T23:59:59+00:00"
generated_at: "2026-06-18T12:53:27.428921+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexaria's DehydraTECH-CBD diabetes study shows weight loss, improved triglycerides and cholesterol in obese rats

## Summary
- 7% body weight loss maintained over 8 weeks in obese diabetic Zucker rats dosed with DehydraTECH-CBD.
- Triglyceride levels over 25% lower at 30 mg/Kg dose vs untreated obese rats (p=0.007).
- Lower dose (30 mg/Kg) improved HDL cholesterol without significant effect on LDL; higher dose increased both.
- Lower dose significantly improved locomotor activity (p<0.05) compared to untreated obese controls.
- Study DIAB-A22-1 conducted by third-party lab in Canada over 8 weeks; no serious health concerns observed.

## SEC filing metadata
- accession: 0001640334-23-000297
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2023-03-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000297/0001640334-23-000297-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033423000297/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-23-000297
- JSON: https://secwatch.observer/filing/0001640334-23-000297.json
- Plain text: https://secwatch.observer/filing/0001640334-23-000297.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.